国际妇产科学杂志 ›› 2023, Vol. 50 ›› Issue (1): 59-64.doi: 10.12280/gjfckx.20220660
收稿日期:
2022-08-16
出版日期:
2023-02-15
发布日期:
2023-03-02
通讯作者:
辛卫娟,E-mail:基金资助:
Received:
2022-08-16
Published:
2023-02-15
Online:
2023-03-02
Contact:
XIN Wei-juan, E-mail: 摘要:
子痫前期(pre-eclampsia,PE)作为妊娠期高血压疾病严重影响母婴健康和远期生存质量,然而对PE的临床干预局限于症状出现后的被动处理,往往造成母婴预后不良,因此对PE的症状前预防研究成为热点。阿司匹林是当前应用最广泛的PE预防性药物,然而随着对PE病因研究的不断深入,诸多药物被证明可用于预防PE。近年来,除阿司匹林以外的抗凝药、抗氧化剂、普伐他汀、二甲双胍及口服微生物组等多种药物在PE的防治研究中取得较大进展。本文综述可用于PE防治的主要药物,以期对临床实践中PE的早期预防有所帮助。
王悦, 辛卫娟. 药物防治子痫前期的研究进展[J]. 国际妇产科学杂志, 2023, 50(1): 59-64.
WANG Yue, XIN Wei-juan. Progress on Pharmacological Prevention and Treatment of Pre-Eclampsia[J]. Journal of International Obstetrics and Gynecology, 2023, 50(1): 59-64.
[1] |
Gestational Hypertension and Preeclampsia: ACOG Practice Bulletin, Number 222[J]. Obstet Gynecol, 2020, 135(6):e237-e260. doi: 10.1097/AOG.0000000000003891.
doi: 10.1097/AOG.0000000000003891 |
[2] |
Staff AC, Fjeldstad HE, Fosheim IK, et al. Failure of physiological transformation and spiral artery atherosis: their roles in preeclampsia[J]. Am J Obstet Gynecol, 2022, 226(2S):S895-S906. doi: 10.1016/j.ajog.2020.09.026.
doi: 10.1016/j.ajog.2020.09.026 |
[3] |
Ma′ayeh M, Costantine MM. Prevention of preeclampsia[J]. Semin Fetal Neonatal Med, 2020, 25(5):101123. doi: 10.1016/j.siny.2020.101123.
doi: 10.1016/j.siny.2020.101123 |
[4] |
de Alwis N, Binder NK, Beard S, et al. Novel approaches to combat preeclampsia: from new drugs to innovative delivery[J]. Placenta, 2020, 102:10-16. doi: 10.1016/j.placenta.2020.08.022.
doi: 10.1016/j.placenta.2020.08.022 pmid: 32980138 |
[5] |
Rolnik DL, Nicolaides KH, Poon LC. Prevention of preeclampsia with aspirin[J]. Am J Obstet Gynecol, 2022, 226(2S):S1108-S1119. doi: 10.1016/j.ajog.2020.08.045.
doi: 10.1016/j.ajog.2020.08.045 |
[6] |
Raia-Barjat T, Edebiri O, Ni Ainle F. Preeclampsia and Venous Thromboembolism: Pathophysiology and Potential Therapy[J]. Front Cardiovasc Med, 2022, 9:856923. doi: 10.3389/fcvm.2022.856923.
doi: 10.3389/fcvm.2022.856923 |
[7] |
Atallah A, Lecarpentier E, Goffinet F, et al. Aspirin for Prevention of Preeclampsia[J]. Drugs, 2017, 77(17):1819-1831. doi: 10.1007/s40265-017-0823-0.
doi: 10.1007/s40265-017-0823-0 pmid: 29039130 |
[8] |
Lin L, Li G, Zhang W, et al. Low-dose aspirin reduces hypoxia-induced sFlt1 release via the JNK/AP-1 pathway in human trophoblast and endothelial cells[J]. J Cell Physiol, 2019, 234(10):18928-18941. doi: 10.1002/jcp.28533.
doi: 10.1002/jcp.28533 pmid: 31004367 |
[9] |
Rolnik DL, Wright D, Poon LC, et al. Aspirin versus Placebo in Pregnancies at High Risk for Preterm Preeclampsia[J]. N Engl J Med, 2017, 377(7):613-622. doi: 10.1056/NEJMoa1704559.
doi: 10.1056/NEJMoa1704559 |
[10] |
Duley L, Meher S, Hunter KE, et al. Antiplatelet agents for preventing pre-eclampsia and its complications[J]. Cochrane Database Syst Rev, 2019, 2019(10): CD004659. doi: 10.1002/14651858.CD004659.pub3.
doi: 10.1002/14651858.CD004659.pub3 |
[11] |
Poon LC, Shennan A, Hyett JA, et al. The International Federation of Gynecology and Obstetrics (FIGO) initiative on pre-eclampsia: A pragmatic guide for first-trimester screening and prevention[J]. Int J Gynaecol Obstet, 2019, 145(Suppl 1):1-33. doi: 10.1002/ijgo.12802.
doi: 10.1002/ijgo.12802 |
[12] |
Cuckle H. Strategies for Prescribing Aspirin to Prevent Preeclampsia: A Cost-Effectiveness Analysis[J]. Obstet Gynecol, 2020, 135(1):217. doi: 10.1097/AOG.0000000000003631.
doi: 10.1097/AOG.0000000000003631 pmid: 31856104 |
[13] |
Wertaschnigg D, Reddy M, Mol B, et al. Evidence-Based Prevention of Preeclampsia: Commonly Asked Questions in Clinical Practice[J]. J Pregnancy, 2019, 2019:2675101. doi: 10.1155/2019/2675101.
doi: 10.1155/2019/2675101 |
[14] |
American College of Obstetricians and Gynecologists′ Committee on Practice Bulletins—Obstetrics, Society for Maternal-Fetal Medicine. Multifetal Gestations: Twin, Triplet, and Higher-Order Multifetal Pregnancies: ACOG Practice Bulletin, Number 231[J]. Obstet Gynecol, 2021, 137(6):e145-e162. doi: 10.1097/AOG.0000000000004397.
doi: 10.1097/AOG.0000000000004397 pmid: 34011891 |
[15] |
Narang K, Szymanski LM. Multiple Gestations and Hypertensive Disorders of Pregnancy: What Do We Know?[J]. Curr Hypertens Rep, 2020, 23(1):1. doi: 10.1007/s11906-020-01107-4.
doi: 10.1007/s11906-020-01107-4 pmid: 33210199 |
[16] |
Benito-Garcia F, Pires I, Lima J. Aspirin Desensitization: Implications for Acetylsalicylic Acid-Sensitive Pregnant Women[J]. Medicina(Kaunas), 2021, 57(4):390. doi: 10.3390/medicina57040390.
doi: 10.3390/medicina57040390 |
[17] |
Zullino S, Clemenza S, Mecacci F, et al. Low Molecular Weight Heparins (LMWH) and Implications along Pregnancy: a Focus on the Placenta[J]. Reprod Sci, 2022, 29(5):1414-1423. doi: 10.1007/s43032-021-00678-0.
doi: 10.1007/s43032-021-00678-0 |
[18] |
Cruz-Lemini M, Vázquez JC, Ullmo J, et al. Low-molecular-weight heparin for prevention of preeclampsia and other placenta-mediated complications: a systematic review and meta-analysis[J]. Am J Obstet Gynecol, 2022, 226(2S):S1126-S1144.e17. doi: 10.1016/j.ajog.2020.11.006.
doi: 10.1016/j.ajog.2020.11.006 |
[19] |
McLaughlin K, Hobson SR, Chandran AR, et al. Circulating maternal placental growth factor responses to low-molecular-weight heparin in pregnant patients at risk of placental dysfunction[J]. Am J Obstet Gynecol, 2022, 226(2S):S1145-S1156.e1. doi: 10.1016/j.ajog.2021.08.027.
doi: 10.1016/j.ajog.2021.08.027 |
[20] |
Miller SL, Wallace EM, Walker DW. Antioxidant therapies: a potential role in perinatal medicine[J]. Neuroendocrinology, 2012, 96(1):13-23. doi: 10.1159/000336378.
doi: 10.1159/000336378 pmid: 22377769 |
[21] |
Hobson SR, Gurusinghe S, Lim R, et al. Melatonin improves endothelial function in vitro and prolongs pregnancy in women with early-onset preeclampsia[J]. J Pineal Res, 2018, 65(3):e12508. doi: 10.1111/jpi.12508.
doi: 10.1111/jpi.12508 |
[22] |
Lanoix D, Guérin P, Vaillancourt C. Placental melatonin production and melatonin receptor expression are altered in preeclampsia: new insights into the role of this hormone in pregnancy[J]. J Pineal Res, 2012, 53(4):417-425. doi: 10.1111/j.1600-079X.2012.01012.x.
doi: 10.1111/j.1600-079X.2012.01012.x pmid: 22686298 |
[23] |
Dou Y, Lin B, Cheng H, et al. The reduction of melatonin levels is associated with the development of preeclampsia: a meta-analysis[J]. Hypertens Pregnancy, 2019, 38(2):65-72. doi: 10.1080/10641955.2019.1581215.
doi: 10.1080/10641955.2019.1581215 pmid: 30794002 |
[24] |
Zuo J, Jiang Z. Melatonin attenuates hypertension and oxidative stress in a rat model of L-NAME-induced gestational hypertension[J]. Vasc Med, 2020, 25(4):295-301. doi: 10.1177/1358863X20919798.
doi: 10.1177/1358863X20919798 pmid: 32469270 |
[25] |
Doğanlar O, Doğanlar ZB, Ovali MA, et al. Melatonin regulates oxidative stress and apoptosis in fetal hearts of pinealectomised RUPP rats[J]. Hypertens Pregnancy, 2020, 39(4):429-443. doi: 10.1080/10641955.2020.1802595.
doi: 10.1080/10641955.2020.1802595 |
[26] |
El-Malkey NF, Aref M, Emam H, et al. Impact of Melatonin on Full-Term Fetal Brain Development and Transforming Growth Factor-β Level in a Rat Model of Preeclampsia[J]. Reprod Sci, 2021, 28(8):2278-2291. doi: 10.1007/s43032-021-00497-3.
doi: 10.1007/s43032-021-00497-3 pmid: 33591564 |
[27] |
Beazley D, Ahokas R, Livingston J, et al. Vitamin C and E supplementation in women at high risk for preeclampsia: a double-blind, placebo-controlled trial[J]. Am J Obstet Gynecol, 2005, 192(2):520-521. doi: 10.1016/j.ajog.2004.09.005.
doi: 10.1016/j.ajog.2004.09.005 pmid: 15695996 |
[28] |
Villar J, Purwar M, Merialdi M, et al. World Health Organisation multicentre randomised trial of supplementation with vitamins C and E among pregnant women at high risk for pre-eclampsia in populations of low nutritional status from developing countries[J]. BJOG, 2009, 116(6):780-788. doi: 10.1111/j.1471-0528.2009.02158.x.
doi: 10.1111/j.1471-0528.2009.02158.x |
[29] |
Wang Z, Wang C, Qiu J, et al. The Association between Dietary Vitamin C/E and Gestational Hypertensive Disorder: A Case-Control Study[J]. J Nutr Sci Vitaminol(Tokyo), 2018, 64(6):454-465. doi: 10.3177/jnsv.64.454.
doi: 10.3177/jnsv.64.454 |
[30] |
Tenório MB, Ferreira RC, Moura FA, et al. Oral antioxidant therapy for prevention and treatment of preeclampsia: Meta-analysis of randomized controlled trials[J]. Nutr Metab Cardiovasc Dis, 2018, 28(9):865-876. doi: 10.1016/j.numecd.2018.06.002.
doi: S0939-4753(18)30190-X pmid: 30111493 |
[31] |
Cardoso PM, Surve S. The Effect of Vitamin E and Vitamin C on the Prevention of Preeclampsia and Newborn Outcome: A Case-Control Study[J]. J Obstet Gynaecol India, 2016, 66(Suppl 1):271-278. doi: 10.1007/s13224-016-0885-z.
doi: 10.1007/s13224-016-0885-z |
[32] |
Esteve-Valverde E, Ferrer-Oliveras R, Gil-Aliberas N, et al. Pravastatin for Preventing and Treating Preeclampsia: A Systematic Review[J]. Obstet Gynecol Surv, 2018, 73(1):40-55. doi: 10.1097/OGX.0000000000000522.
doi: 10.1097/OGX.0000000000000522 pmid: 29368790 |
[33] |
Ahmed A, Williams DJ, Cheed V, et al. Pravastatin for early-onset pre-eclampsia: a randomised, blinded, placebo-controlled trial[J]. BJOG, 2020, 127(4):478-488. doi: 10.1111/1471-0528.16013.
doi: 10.1111/1471-0528.16013 |
[34] |
de Alwis N, Beard S, Mangwiro YT, et al. Pravastatin as the statin of choice for reducing pre-eclampsia-associated endothelial dysfunction[J]. Pregnancy Hypertens, 2020, 20:83-91. doi: 10.1016/j.preghy.2020.03.004.
doi: S2210-7789(20)30031-3 pmid: 32199147 |
[35] |
Costantine MM, Tamayo E, Lu F, et al. Using pravastatin to improve the vascular reactivity in a mouse model of soluble fms-like tyrosine kinase-1-induced preeclampsia[J]. Obstet Gynecol, 2010, 116(1):114-120. doi: 10.1097/AOG.0b013e3181e10ebd.
doi: 10.1097/AOG.0b013e3181e10ebd pmid: 20567176 |
[36] |
McDonnold M, Tamayo E, Kechichian T, et al. The effect of prenatal pravastatin treatment on altered fetal programming of postnatal growth and metabolic function in a preeclampsia-like murine model[J]. Am J Obstet Gynecol, 2014, 210(6):542.e1-e7. doi: 10.1016/j.ajog.2014.01.010.
doi: 10.1016/j.ajog.2014.01.010 |
[37] |
Gajzlerska-Majewska W, Bomba-Opon DA, Wielgos M. Is pravastatin a milestone in the prevention and treatment of preeclampsia?[J]. J Perinat Med, 2018, 46(8):825-831. doi: 10.1515/jpm-2017-0109.
doi: 10.1515/jpm-2017-0109 pmid: 29570452 |
[38] |
Kräker K, O′Driscoll JM, Schütte T, et al. Statins Reverse Postpartum Cardiovascular Dysfunction in a Rat Model of Preeclampsia[J]. Hypertension, 2020, 75(1):202-210. doi: 10.1161/HYPERTENSIONAHA.119.13219.
doi: 10.1161/HYPERTENSIONAHA.119.13219 pmid: 31786987 |
[39] |
Vahedian-Azimi A, Karimi L, Reiner Ž, et al. Effects of statins on preeclampsia: A systematic review[J]. Pregnancy Hypertens, 2021, 23:123-130. doi: 10.1016/j.preghy.2020.11.014.
doi: 10.1016/j.preghy.2020.11.014 pmid: 33333432 |
[40] |
Poniedziałek-Czajkowska E, Mierzyński R, Dńuski D, et al. Prevention of Hypertensive Disorders of Pregnancy-Is There a Place for Metformin?[J]. J Clin Med, 2021, 10(13):2805. doi: 10.3390/jcm10132805.
doi: 10.3390/jcm10132805 |
[41] |
Racine JL, Adams JH, Antony KM, et al. Metformin Exposure and Risk of Hypertensive Disorders of Pregnancy in Patients with Type 2 Diabetes[J]. Am J Perinatol, 2021, 38(11):1103-1108. doi: 10.1055/s-0041-1728821.
doi: 10.1055/s-0041-1728821 |
[42] |
Brownfoot FC, Hastie R, Hannan NJ, et al. Metformin as a prevention and treatment for preeclampsia: effects on soluble fms-like tyrosine kinase 1 and soluble endoglin secretion and endothelial dysfunction[J]. Am J Obstet Gynecol, 2016, 214(3):356.e1-356.e15. doi: 10.1016/j.ajog.2015.12.019.
doi: 10.1016/j.ajog.2015.12.019 |
[43] |
Wang F, Cao G, Yi W, et al. Effect of Metformin on a Preeclampsia-Like Mouse Model Induced by High-Fat Diet[J]. Biomed Res Int, 2019, 2019:6547019. doi: 10.1155/2019/6547019.
doi: 10.1155/2019/6547019 |
[44] |
Alqudah A, McKinley MC, McNally R, et al. Risk of pre-eclampsia in women taking metformin: a systematic review and meta-analysis[J]. Diabet Med, 2018, 35(2):160-172. doi: 10.1111/dme.13523.
doi: 10.1111/dme.13523 |
[45] |
Bao LX, Shi WT, Han YX. Metformin versus insulin for gestational diabetes: a systematic review and meta-analysis[J]. J Matern Fetal Neonatal Med, 2021, 34(16):2741-2753. doi: 10.1080/14767058.2019.1670804.
doi: 10.1080/14767058.2019.1670804 |
[46] |
Kalafat E, Sukur YE, Abdi A, et al. Metformin for prevention of hypertensive disorders of pregnancy in women with gestational diabetes or obesity: systematic review and meta-analysis of randomized trials[J]. Ultrasound Obstet Gynecol, 2018, 52(6):706-714. doi: 10.1002/uog.19084.
doi: 10.1002/uog.19084 pmid: 29749110 |
[47] |
Bardos J, Fiorentino D, Longman RE, et al. Immunological Role of the Maternal Uterine Microbiome in Pregnancy: Pregnancies Pathologies and Alterated Microbiota[J]. Front Immunol, 2019, 10:2823. doi: 10.3389/fimmu.2019.02823.
doi: 10.3389/fimmu.2019.02823 pmid: 31969875 |
[48] |
Miao T, Yu Y, Sun J, et al. Decrease in abundance of bacteria of the genus Bifidobacterium in gut microbiota may be related to pre-eclampsia progression in women from East China[J]. Food Nutr Res, 2021 Jun 28;65. doi: 10.29219/fnr.v65.5781.
doi: 10.29219/fnr.v65.5781 |
[49] |
Sohn K, Underwood MA. Prenatal and postnatal administration of prebiotics and probiotics[J]. Semin Fetal Neonatal Med, 2017, 22(5):284-289. doi: 10.1016/j.siny.2017.07.002.
doi: S1744-165X(17)30067-7 pmid: 28720399 |
[50] |
Brantsaeter AL, Myhre R, Haugen M, et al. Intake of probiotic food and risk of preeclampsia in primiparous women: the Norwegian Mother and Child Cohort Study[J]. Am J Epidemiol, 2011, 174(7):807-815. doi: 10.1093/aje/kwr168.
doi: 10.1093/aje/kwr168 pmid: 21821542 |
[51] |
Holscher HD. Dietary fiber and prebiotics and the gastrointestinal microbiota[J]. Gut Microbes, 2017, 8(2):172-184. doi: 10.1080/19490976.2017.1290756.
doi: 10.1080/19490976.2017.1290756 pmid: 28165863 |
[52] |
Marques FZ, Nelson E, Chu PY, et al. High-Fiber Diet and Acetate Supplementation Change the Gut Microbiota and Prevent the Development of Hypertension and Heart Failure in Hypertensive Mice[J]. Circulation, 2017, 135(10):964-977. doi: 10.1161/CIRCULATIONAHA.116.024545.
doi: 10.1161/CIRCULATIONAHA.116.024545 pmid: 27927713 |
[1] | 邓玲玲, 伍绍文, 张为远. 小剂量阿司匹林在子痫前期预防中的研究进展[J]. 国际妇产科学杂志, 2024, 51(5): 515-518. |
[2] | 吴志韦, 林雪燕, 张雪芹, 杨梅琳. 子痫前期预防、预测的现状与关注焦点[J]. 国际妇产科学杂志, 2024, 51(3): 312-316. |
[3] | 寿梦娜, 黄艺舟, 周坚红. 褪黑素与早发性卵巢功能不全关系的研究进展[J]. 国际妇产科学杂志, 2024, 51(2): 133-136. |
[4] | 刘湘, 敖凯, 高艺苇, 吴琼, 穆玉兰. 维生素E对围绝经期和绝经后妇女健康的影响[J]. 国际妇产科学杂志, 2024, 51(1): 93-98. |
[5] | 文清, 柒铭铭, 赖慧敏, 谢恺俐, 王铭远. 白藜芦醇在子痫前期中的作用机制及研究进展[J]. 国际妇产科学杂志, 2021, 48(4): 371-375. |
[6] | 夏颖, 邓燕杰. 子宫内膜异位症与晚期不良妊娠结局的研究进展[J]. 国际妇产科学杂志, 2021, 48(1): 15-20. |
[7] | 彭丽娜, 安春晓, 张广美. 子宫内膜异位症的药物治疗[J]. 国际妇产科学杂志, 2020, 47(6): 694-698. |
[8] | 顾雨玲, 韩冰. 阿司匹林和低分子肝素预防子痫前期的研究进展[J]. 国际妇产科学杂志, 2020, 47(3): 253-257. |
[9] | 张艳红,李洁,苏婧,李增彦. 子痫前期高危孕妇阿司匹林抵抗与基因多态性相关性[J]. 国际妇产科学杂志, 2019, 46(4): 407-411. |
[10] | 彭兰,吴晓,康燕,姚仪倩,洪湘兰. fullPIERS预测模型在398例子痫前期人群中的外部确认 [J]. 国际妇产科学杂志, 2019, 46(1): 62-66. |
[11] | 史海霞,李桂青,符婷,辜叶龙,吴思雨. 低分子肝素在产科常见疾病中的应用[J]. 国际妇产科学杂志, 2018, 45(6): 681-685. |
[12] | 崔金帅,林浩,张小鹏,高秉仁. 心脏机械瓣膜置换术后妊娠期女性抗凝选择的研究进展[J]. 国际妇产科学杂志, 2018, 45(3): 263-266. |
[13] | 赵霞,王伟,郝敏. 阿司匹林及低分子肝素在子痫前期中应用的研究进展[J]. 国际妇产科学杂志, 2018, 45(2): 141-144. |
[14] | 于津,孙峰#,郭玉娜,张晨. 妊娠早期同型半胱氨酸和血脂水平对重度子痫前期的预测价值[J]. 国际妇产科学杂志, 2018, 45(1): 51-54. |
[15] | 陈志敏,牛阳,刘肖,赵双一. 熊去氧胆酸联合低分子肝素钙注射液与丁二磺酸腺苷蛋氨酸治疗妊娠期肝内胆汁淤积症的临床研究[J]. 国际妇产科学杂志, 2017, 44(6): 642-646. |
阅读次数 | ||||||
全文 |
|
|||||
摘要 |
|
|||||